- |||||||||| 3K3A-APC / ZZ Biotech
Intravenous 3K3A-Activated Protein C Inhibits Murine Ocular Inflammation and Suppresses Ocular Choroidal Neovascularization (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_3537; Drawing insights from the neuroprotective activities of 3K3A-APC in the brain and CNS and recognizing the retina, particularly the macula, as an extension of the brain, we propose 3K3A-APC as a potential neuroprotective treatment for AMD and other neurodegenerative retinal pathologies. Given the established safety of systemic 3K3A-APC administration in phase 2 clinical trials for ischemic stroke, our findings support further exploring 3K3A-APC as a novel therapeutic approach in ophthalmology.
- |||||||||| 3K3A-APC / ZZ Biotech
Journal: Analysis of Brain Edema in RHAPSODY. (Pubmed Central) - Jun 29, 2023 Existing cerebral edema imaging markers potentially describe two distinct processes, including lesional water concentration (i.e., NWU) and mass effect (MLS, HVR, and CSF volume). These two types of imaging markers may represent distinct aspects of cerebral edema, which could be useful for future trials targeting this process.
- |||||||||| 3K3A-APC / ZZ Biotech
Parmodulin, an Allosteric Inhibitor of Protease Activated Receptor 1 (PAR1) Protects Sickle Cell Mice from Thromboinflammation and Endothelial Dysfunction (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_3773; 3K3A-APC is a signaling selective variant of APC that activates cytoprotective PAR1 signaling with minimal anticoagulant effects, demonstrated to have a beneficial role in stroke models...In contrast, PM2-mediated allosteric inhibition of thrombin/PAR1 and simultaneous induction of APC-like cytoprotective signaling attenuated levels of TAT, IL-6, HMGB1, and sVCAM in HbSS mice. Future studies towards evaluating the effect of PM2 on downstream targets of PAR1 signaling in sickle mice will provide more insight into the mechanism of this protective effect.
- |||||||||| 3K3A-APC / ZZ Biotech
Activated protein C analog protects pericyte-deficient mice from ischemic brain injury (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_4247; Our data suggest that pericyte deficiency results in greater brain injury, BBB breakdown, and neuronal degeneration in stroked mice and that 3K3A-APC protects the brain from accelerated injury caused by pericyte deficiency. These findings may have implications for treatment of ischemic brain injury in neurological conditions associated with pericyte loss such as those seen during normal aging and in neurodegenerative disorders such as Alzheimer's disease.
- |||||||||| 3K3A-APC / ZZ Biotech
Trial completion: 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 28, 2022 P2, N=16, Completed, These findings may have implications for treatment of ischemic brain injury in neurological conditions associated with pericyte loss such as those seen during normal aging and in neurodegenerative disorders such as Alzheimer's disease. Recruiting --> Completed
- |||||||||| 3K3A-APC / ZZ Biotech
Trial completion date, Trial primary completion date: 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 24, 2022 P2, N=16, Recruiting, Thus, p21-dependent tubular senescence is a pathway contributing to the hyperglycemic memory, which can be therapeutically targeted. Trial completion date: Mar 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Sep 2022
- |||||||||| 3K3A-APC / ZZ Biotech
Rhapsody-2: A Phase 3 Study Of 3K3A-APC In Acute Ischemic Stroke (Hall B2, Poster Hall; Board No. CTP19) - Feb 22, 2022 - Abstract #ISC2022ISC_1739; The primary outcome is 90-day disability measured by modified Rankin score (mRS) using ordinal (shift) analysis. Secondary analyses include additional behavioral outcomes, lesion morphometry, and qualify of life measures.
- |||||||||| 3K3A-APC / ZZ Biotech
Journal: Cerebroprotection for Acute Ischemic Stroke: Looking Ahead. (Pubmed Central) - Jan 11, 2022 Examples of pleiotropic treatments include therapeutic hypothermia and 3K3A-APC (activated protein C)...Before clinical trials, preclinical assessment could include subjects that are aged, of both sexes, and harbor comorbid conditions such as diabetes or hypertension. With these new definitions, novel approaches, and renewed attention to rigor, the prospect for successful cerebroprotective therapy should improve.
- |||||||||| 3K3A-APC / ZZ Biotech
Preclinical, Journal: Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. (Pubmed Central) - Jan 4, 2022 We show that PAR1 and PAR3 were also required for 3K3A-APC's suppression of post-WM stroke microglia and astrocyte responses and overall improvement in neuropathologic and functional outcomes. Our data provide new insights into the neuroprotective APC pathway in the WM and illustrate 3K3A-APC's potential for treating WM stroke in humans, possibly including multiple WM strokes that result in vascular dementia.
- |||||||||| 3K3A-APC / ZZ Biotech
Enrollment open: 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Dec 6, 2021 P2, N=16, Recruiting, Our data provide new insights into the neuroprotective APC pathway in the WM and illustrate 3K3A-APC's potential for treating WM stroke in humans, possibly including multiple WM strokes that result in vascular dementia. Not yet recruiting --> Recruiting
- |||||||||| 3K3A-APC / ZZ Biotech
Trial primary completion date, Combination therapy: RHAPSODY: Safety Evaluation of 3K3A-APC in Ischemic Stroke (clinicaltrials.gov) - Mar 15, 2017 P2, N=100, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Mar 2017 --> Jul 2017
|